STOCK TITAN
  1. Home
  2. News
  3. GH

Guardant Health Inc - GH STOCK NEWS

Welcome to our dedicated news page for Guardant Health (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.

News
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. The Shield test, which can detect cancer in its early stages by analyzing circulating tumor DNA (ctDNA), achieved 83% sensitivity and 90% specificity in a pivotal study. Early detection is crucial as colorectal cancer is one of the leading causes of cancer-related deaths in South Korea. The Shield test has shown approximately 90% adherence in a real-world clinical setting, addressing the low compliance rates associated with traditional screening methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
News
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Rhea-AI Summary
Guardant Health, Inc. reported a 22% increase in Q3 revenue compared to the previous year, driven by a 35% growth in clinical volume. The company raised its 2023 revenue guidance to $553 to $556 million. Other highlights include the presentation of MRD data for the PEGASUS trial and the launch of Guardant360 in Japan and China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
earnings
-
News
Guardant Health to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will be participating in two upcoming investor conferences: Jefferies 14th Annual Global Healthcare Conference in London, UK on November 16 at 9:00 a.m. GMT and Piper Sandler 35th Annual Healthcare Conference in New York, NY on November 28 at 9:30 a.m. ET. Interested parties can access live and archived webcasts of the sessions on the company website at www.guardanthealth.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
conferences
News
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
Rhea-AI Summary
Guardant Health and Flatiron Health announce an initiative to integrate Guardant's genomic profiling tests within Flatiron's OncoEMR tool. This integration streamlines access to critical data for over 2,000 clinicians within the Flatiron network, simplifying workflows and saving time in the ordering process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
News
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Rhea-AI Summary
Initial results from the PEGASUS trial suggest that Guardant Health's circulating tumor DNA blood test can be used to guide post-surgical chemotherapy regimens for patients with stage III or high-risk stage II colon cancer. The study found that patients with positive liquid biopsy results had a higher risk of cancer recurrence, while those with negative results had a lower risk. The test can help reduce unnecessary toxicity from chemotherapy and improve treatment outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
earnings
-
News
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
Rhea-AI Summary
Guardant Health, Inc. will report Q3 2023 financial results on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences earnings
News
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
Rhea-AI Summary
Geisinger Health Plan now covers Guardant Reveal MRD test for colorectal cancer patients after curative treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
News
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Rhea-AI Summary
Guardant Health's Guardant360 CDx liquid biopsy test approved as a companion diagnostic for HER2-targeted therapy in Japan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
Rhea-AI Summary
Guardant Health announces closure of COBRA study on MRD testing in colon cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.41%
Tags
none
News
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
Guardant Health to participate in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.41%
Tags
conferences
Stock GH logo
Guardant Health Inc

Nasdaq:GH

GH Rankings

#1842 Ranked by Market Cap
#4656 Ranked by Stock Gains
N/A Ranked by Dividends

GH Stock Data

2.22B
116.64M
4.15%
92.14%
6.28%
Dental Laboratories
Manufacturing
Link
United States
Palo Alto

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.